Trial Profile
A compassionate use study of R435(Bevacizumab) in chemotherapy naive and inoperable malignant pleural mesothelioma patients
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 04 Dec 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cisplatin; Pemetrexed
- Indications Malignant-mesothelioma
- Focus Adverse reactions; Registrational
- Sponsors Chugai Pharmaceutical
- 19 May 2017 Status changed from recruiting to discontinued.
- 14 Dec 2016 New trial record